Indena unveils enhanced HPAPI and targeted therapy capabilities at DCAT Week 2026

Milan, 24^th March, 2026 – Indena, the Italian global leader in the pharmaceutical industry and in CDMO services for high-quality active pharmaceutical ingredients, is proud to announce its participation at DCAT Week 2026 (March 23-26, 2026, New York), where it will highlight its significantly expanded capabilities in Highly Potent Active Pharmaceutical Ingredients (HPAPIs), Antibody-Drug Conjugates (ADCs), and advancements in Peptide Drug Conjugates (PDCs) through targeted strategic collaborations.

With over 35 years of unparalleled experience in the development and manufacturing of HPAPIs, Indena continues to solidify its position as a global leader. The company currently produces 10 commercial and 13 clinical-phase HPAPIs, supported by a robust R&D team and a dedicated CDMO division that delivers customized, end-to-end solutions — from early clinical development to commercial supply. Indena integrates advanced technologies—semisynthesis, chemical synthesis, microbial fermentation, and plant extraction—providing full flexibility in the processing of complex molecules.

Indena's highly advanced Settala site in Italy is equipped to handle substances with Occupational Exposure Limits (OEL) as low as 1 ng/m³, a testament to over 30 years of expertise in safe handling and high-containment facilities. Continuous investments in advanced GMP lines, high-containment laboratories and fermentation capacity enable the production of Class 5 HPAPIs compounds at an industrial scale, while maintaining the highest standards of safety, quality, and environmental protection.

The growing landscape of oncology New Chemical Entities (NCEs), Antibody-Drug Conjugates (ADCs), and personalized medicine approaches drives an increasing demand for specialized CDMO services. Indena leverages its long-standing expertise in high-potency compounds to support oncology-focused innovation, including the development and manufacturing of toxin-based payloads and linkers for ADCs. Through backward integration in microbial fermentation and high-containment downstream processing, Indena ensures a reliable and independent supply chain for critical ADC components. The company's ongoing investments are proactively expanding its capacity to meet the future needs of the oncology market, offering fully integrated and technologically advanced solutions for targeted therapies. By integrating fully contained freeze-drying within glove boxes, Indena elevates its High Potency platform, combining advanced particle engineering with maximum containment for safe and efficient HPAPI manufacturing.

Further reinforcing its commitment to innovation and the delivery of comprehensive solutions to its clients, Indena is pursuing strategic interest in advancing Peptide Drug Conjugate (PDC), through collaborative models.

“Our continuous investments across our global operations, from advanced GMP lines and high-containment laboratories to expanded precision fermentation capacity, underscore Indena's unwavering commitment to innovation and safety in HPAPI manufacturing, achieving OELs as low as 1 ng/m³ - says Bernard Vianes, Global CDMO Director at Indena -. Moreover, we’re working to complement our core strengths and expand our offering in the rapidly evolving landscape of targeted therapies, providing clients with increasingly comprehensive and highly advanced solutions for ADCs and PDCs”.

Stefano Togni, Chief Commercial Officer at Indena, adds: “In today’s dynamic pharmaceutical market, especially for specialized oncology and high-potency compounds, clients demand more than just capacity; they seek integrated expertise, flexibility, and unwavering reliability. Indena delivers this through our comprehensive, end-to-end solutions, continuously enhanced by strategic investments and our deep knowledge of complex molecules. Our continuous investment in advanced technologies and our deep expertise in complex molecules ensures we deliver the scientific depth and operational excellence our partners need to bring innovative medicines to patients faster”.

Indena is particularly focused on empowering small and mid-sized pharmaceutical and biotech companies, acting as a strategic CDMO partner by offering agile, high-quality development and manufacturing solutions specifically tailored to their project lifecycle. Its specialized facilities and integrated services — from early-stage R&D to scalable GMP production — ensure seamless progression from initial clinical phases to commercial supply. With customized solutions, including dedicated equipment and advanced high-containment infrastructure, Indena provides emerging and growing companies with a technically advanced and fully integrated partner essential for navigating complex and innovative pharmaceutical development pathways.